FOR IMMEDIATE RELEASE
ACS News Service Weekly PressPac: June 23, 2021
Seeking a treatment for IBS pain in tarantula venom
ACS Pharmacology & Translational Science
For patients who have inflammatory bowel syndrome (IBS), the condition is literally a pain in the gut. Chronic 鈥� or long-term 鈥� abdominal pain is common, and there are currently no effective treatment options for this debilitating symptom. In a new study in听ACS Pharmacology & Translational Science, researchers identify a new potential source of relief: a molecule derived from spider venom. In experiments with mice, they found that one dose could stop symptoms associated with IBS pain.听
The sensation of pain originates in electrical signals carried from the body to the brain by cells called neurons. Tiny channels in the surfaces of neurons help them transmit these signals by allowing positively charged sodium ions to pass into the cell. There are numerous types of sodium channels, and some pain-killing drugs work by blocking them. However, existing treatments interfere with channels indiscriminately and can only be used briefly 鈥� not for chronic pain. Stuart Brierley, Glenn King and colleagues wanted to find a way to selectively target the channels activated during chronic IBS pain. 听
The researchers focused on a particular sodium channel they suspected was responsible for chronic IBS pain. Then, to block it, they turned to the richest known source of molecules that alter the activity of sodium channels: spider venom. In the venom of a Peruvian tarantula, they discovered a molecule that they named Tsp1a, which had promising blocking activity. To test its potential as a treatment, the researchers used mice that had an IBS-related condition, and they monitored the mice during the experiment to detect a reflex associated with pain. A single Tsp1a treatment delivered into the mice鈥檚 colons significantly reduced the occurrence of this reflex, indicating pain relief. What鈥檚 more, Tsp1a appeared highly selective and did not interfere with other body functions, suggesting it could be used safely in humans. While Tsp1a shows promise as a potential treatment for chronic IBS pain, thorough studies of its activity in the body and the immune system鈥檚 reaction to it will be critical, the researchers write.
The authors acknowledge funding from the听, the听, the听听补苍诲听. Four of the authors are co-inventors on a U.S. patent application that covers the sequence, derivatives and methods of use for Tsp 1a.听
听
###
The American Chemical 中国365bet中文官网 (ACS) is a nonprofit organization founded in 1876 and chartered by the U.S. Congress. ACS is committed to improving all lives through the transforming power of chemistry. Its mission is to advance scientific knowledge, empower a global community and champion scientific integrity, and its vision is a world built on science. The 中国365bet中文官网 is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, e-books and weekly news periodical听Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world鈥檚 scientific knowledge. ACS鈥� main offices are in Washington, D.C., and Columbus, Ohio.
Registered journalists can subscribe to the to access embargoed and public science press releases. For media inquiries, contact newsroom@acs.org.
Note: ACS does not conduct research but publishes and publicizes peer-reviewed scientific studies.
Media Contact
ACS Newsroom
newsroom@acs.org
###
La sociedad American Chemical 中国365bet中文官网 (ACS) es una organizaci贸n sin fines de lucro fundada en 1876 y aprobada por el Congreso de los Estados Unidos. La ACS se ha comprometido a mejorar la vida de todas las personas mediante la transformaci贸n del poder de la qu铆mica. Su misi贸n es promover el conocimiento cient铆fico, empoderar a la comunidad global y defender la integridad cient铆fica, y su visi贸n es un mundo construido bas谩ndose en la ciencia. La Sociedad es l铆der mundial en la promoci贸n de la excelencia en la educaci贸n cient铆fica y en el acceso a informaci贸n e investigaci贸n relacionadas con la qu铆mica a trav茅s de sus m煤ltiples soluciones de investigaci贸n, publicaciones revisadas por expertos, conferencias cient铆ficas, libros electr贸nicos y noticias semanales peri贸dicas de Chemical & Engineering News. Las revistas de la ACS se encuentran entre las m谩s citadas, las m谩s fiables y las m谩s le铆das en la literatura cient铆fica; sin embargo, la propia ACS no realiza investigaci贸n qu铆mica. Como l铆der en soluciones de informaci贸n cient铆fica, su divisi贸n CAS se asocia con innovadores internacionales para acelerar los avances mediante la preservaci贸n, la conexi贸n y el an谩lisis de los conocimientos cient铆ficos del mundo. Las sedes principales de la ACS se encuentran en Washington, D.C., y Columbus, Ohio.
Los periodistas registrados pueden suscribirse al en EurekAlert! para acceder a comunicados de prensa p煤blicos y retenidos.听 Para consultas de los medios, comun铆quese con newsroom@acs.org.
Nota: ACS no realiza investigaciones, pero publica y divulga estudios cient铆ficos revisados por expertos.鈥�
;void(0);){kind=link}